GMP Grade Ergothioneine Food Bulk Raw Materials For Dietary Supplements

Dr.Ergo® L-Ergothioneine is a high-purity functional nutrition ingredient developed for mitochondrial health, healthy-aging, active-lifestyle and research-led dietary supplement formulations.

With an L-Ergothioneine content of ≥99.99%, Dr.Ergo® provides B2B customers with a standardized active ingredient for the development of capsules, tablets, powders, gummies, jellies, functional beverages, coffee products and other nutrition applications.

L-Ergothioneine, commonly abbreviated as EGT, is a naturally occurring sulfur-containing amino acid derivative found in certain mushrooms and microorganisms. It is obtained through the diet and transported into cells through SLC22A4, commonly referred to as OCTN1 or the ergothioneine transporter.

Beyond its established connection with antioxidant and cellular protection research, EGT is increasingly being investigated in relation to mitochondrial biology and cellular energy metabolism.

A study published in Cell Metabolism in 2025 reported that EGT accumulated in skeletal-muscle mitochondria following exercise training and identified 3-mercaptopyruvate sulfurtransferase, or MPST, as a direct molecular target of EGT. In biochemical, cellular and mouse experiments, EGT activated MPST and increased mitochondrial respiration. Dietary EGT supplementation was also associated with improved exercise-training performance in mice. These results provide a specific mechanistic direction for EGT research, although they do not establish equivalent energy or exercise-performance effects in humans.

Other laboratory studies have examined EGT in models involving mitochondrial oxidative stress, mitochondrial membrane potential, ATP depletion and cellular injury. These studies support further investigation of EGT as a mitochondrial research ingredient, but the current evidence base remains primarily mechanistic and preclinical.

Dr.Ergo® may therefore be considered for formulation concepts related to:

• Mitochondrial function research
• Cellular energy metabolism
• Healthy aging
• Active-lifestyle nutrition
• Exercise and recovery concepts
• Antioxidant support
• Cellular resilience
• Daily vitality

Compared with mushroom extracts and general botanical materials, Dr.Ergo® provides a defined L-Ergothioneine active content. Its high purity, crystalline powder form and biofermentation-derived production route support accurate dosage design, batch consistency and professional B2B quality documentation.

Final formulations, recommended use levels and product claims should be assessed according to the intended dosage form, target population, destination market and applicable regulatory requirements.

The clearly defined L-Ergothioneine content supports accurate dosage calculation, consistent formulation design and reliable finished-product development.

Unlike mushroom extracts containing multiple naturally occurring compounds, Dr.Ergo® provides a standardized active ingredient profile that can simplify formulation calculations, ingredient specifications and quality control.

Recent research has identified MPST as a direct molecular target of EGT.

MPST is a mitochondrial enzyme involved in sulfur metabolism and cellular bioenergetics. The reported interaction between EGT and MPST provides a more specific mechanistic basis for discussing EGT in relation to mitochondrial respiration than relying solely on general antioxidant terminology.

The current findings are based primarily on biochemical, cellular and mouse experiments. They should therefore be described as an emerging research mechanism rather than confirmation of increased energy production or physical performance in humans.

EGT has been investigated for its relationship with mitochondrial respiration and metabolic adaptation.

In the 2025 Cell Metabolism study, EGT increased mitochondrial respiration through MPST activation in experimental systems. The study also reported accumulation of EGT in skeletal-muscle mitochondria following exercise training. These findings provide a research foundation for mitochondrial and active-lifestyle formulations, while controlled human intervention data remain limited.

Cell-based studies have examined whether EGT may help protect mitochondrial structures and functions under oxidative-stress conditions.

In a human brain endothelial cell model, EGT reduced several changes associated with experimentally induced mitochondrial injury, including elevated mitochondrial reactive oxygen species, reduced mitochondrial membrane potential and decreased ATP levels. These findings are relevant to preclinical ingredient research but do not establish a corresponding clinical benefit in consumers.

A 2024 scientific review concluded that EGT has promising mitochondrial-protection potential while also emphasizing that its direct uptake into mitochondria has not been definitively established across biological systems. External communications should reflect this remaining uncertainty.

Mitochondrial function, oxidative-stress regulation and cellular resilience are important research themes within healthy-aging science.

Dr.Ergo® can therefore be considered for healthy-aging products that require a research-led mitochondrial narrative. The ingredient should not be described as reversing aging, restoring youthful metabolism or extending human lifespan.

Dr.Ergo® may be evaluated for active-lifestyle and sports-nutrition formulations built around:

• Mitochondrial research
• Cellular resilience
• Exercise-related oxidative stress
• Metabolic adaptation
• Daily vitality
• Healthy aging

Animal research provides a basis for continued investigation, but it should not be converted into guaranteed human endurance, recovery or exercise-performance claims.

The controlled biofermentation process provides a standardized alternative to mushroom extraction and other natural extract materials.

This production route supports consistent active content, stable ingredient quality and scalable commercial supply for B2B customers.

The white to off-white crystalline powder can be evaluated for use in:

• Capsules
• Tablets
• Sachets
• Powder blends
• Gummies
• Functional jellies
• Coffee products
• Functional beverages
• Ready-to-mix nutrition products

Processing compatibility, sensory performance and finished-product stability should be confirmed through formulation testing.

The water-soluble profile of Dr.Ergo® allows it to be evaluated for functional beverages, coffee products and ready-to-mix powder systems.

Actual dissolution rate, clarity, taste, pH compatibility, heat tolerance and shelf-life performance should be tested in the complete formulation.

Supporting documents can assist purchasing, quality, regulatory and product-development teams during ingredient evaluation.

Available documentation may include:

• Certificate of Analysis
• Product specification sheet
• Identity and purity testing
• Heavy-metal testing
• Microbiological testing
• Residual solvent information, where applicable
• Allergen statement
• GMO statement
• Stability information
• Storage and handling guidance
• Applicable regulatory support documents

The availability and scope of each document should be confirmed according to the selected product grade and intended market.

Dr.Ergo® may be considered for formulations developed around mitochondrial function, cellular resilience and energy-metabolism research.

The ingredient should not be described as clinically proven to increase ATP production, repair mitochondria or directly energize human cells.

Dr.Ergo® can be incorporated into healthy-aging formulations designed around:

• Mitochondrial health research
• Antioxidant nutrition
• Cellular resilience
• Daily vitality
• Active aging
• Healthy longevity concepts

Healthy-aging positioning should remain distinct from anti-disease, age-reversal or lifespan-extension claims.

EGT may provide a differentiated ingredient direction for active-lifestyle products where the formulation narrative focuses on mitochondrial adaptation and exercise-related oxidative-stress research.

Experimental studies provide relevant mechanistic evidence, but human sports-performance outcomes have not been established sufficiently to support strong performance claims.

Dr.Ergo® may be evaluated alongside other ingredients commonly used in mitochondrial and energy formulations, including:

• Coenzyme Q10
• Nicotinamide-related ingredients
• B vitamins
• Magnesium
• Amino acids
• Polyphenols
• Other antioxidant ingredients

Compatibility, use levels, sensory performance, stability and regulatory suitability must be evaluated in the final product. The inclusion of multiple ingredients does not by itself establish synergy.

Potential application formats include:

• Functional beverages
• Coffee products
• Ready-to-mix powders
• Gummies
• Jellies
• Powder sachets
• Capsules
• Tablets

Finished-product testing should evaluate processing temperature, pH, light exposure, oxygen exposure, ingredient interactions and storage conditions.

The following language is more consistent with the current research foundation:

• Studied for its relationship with mitochondrial function
• Investigated in mitochondrial respiration research
• Associated with cellular energy-metabolism research
• Supported by emerging mechanistic and preclinical evidence
• Identified as an interaction partner and activator of MPST in experimental research
• Investigated in models of mitochondrial oxidative stress
• Suitable for research-led healthy-aging formulations
• Studied for cellular resilience under oxidative-stress conditions

The following expressions should not be used as established product claims:

• Boosts human energy
• Enhances physical strength
• Improves human metabolism
• Clinically increases ATP production
• Repairs damaged mitochondria
• Reverses mitochondrial aging
• Eliminates fatigue
• Improves exercise performance
• Accelerates recovery
• Guarantees greater endurance
• Precisely targets mitochondria
• Delivers EGT directly to specific tissues
• Makes energy metabolism more efficient

The mitochondrial evidence base currently includes:

• Biochemical interaction studies
• Cell-based experiments
• Animal studies
• Mechanistic research
• Scientific reviews
• Limited direct human evidence

These categories should not be presented as equivalent.

A result observed in isolated enzymes or cultured cells establishes a mechanistic possibility. A result observed in mice supports biological plausibility but does not prove the same outcome in humans. Human observational evidence may identify associations but cannot establish causation. Controlled human intervention studies are required to substantiate specific consumer outcomes.

Before commercial use, customers should evaluate Dr.Ergo® under the actual conditions of the finished product, including:

• Target daily intake
• Dosage form
• Processing temperature
• Product pH
• Ingredient compatibility
• Solubility and dispersion
• Sensory performance
• Finished-product stability
• Packaging system
• Label-claim feasibility
• Local regulatory requirements

All finished-product claims should be reviewed according to the complete formulation, recommended intake, intended population, product category and destination market.

EFSA has evaluated specified synthetic L-Ergothioneine novel-food materials and concluded that the assessed ingredients were safe under the proposed conditions of use. These conclusions apply to the specific materials, specifications, intended populations and use levels included in the respective applications. They should not be interpreted as universal authorization for every EGT ingredient or finished product.

The regulatory status of Dr.Ergo® and its intended application must be confirmed separately for each destination market.